O-desulfated heparin inhalation - ParinGenix

Drug Profile

O-desulfated heparin inhalation - ParinGenix

Alternative Names: PGX-200

Latest Information Update: 17 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ParinGenix
  • Class Anti-inflammatories; Antiasthmatics; Blood proteins; Heparins; Ischaemic heart disorder therapies
  • Mechanism of Action Cathepsin G inhibitors; Leucocyte elastase inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute asthma; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 30 Mar 2005 Preclinical trials in Acute asthma in USA (Inhalation)
  • 30 Mar 2005 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
  • 30 Mar 2005 Preclinical trials in Cystic fibrosis in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top